Copyright © 1999 by the European Society of Cardiology.
MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience
Received October 4, 1998; accepted October 14, 1998Abstract
Aims In observational studies, prolonged lower blood total cholesterol levels—down at least to 3mmol.l–1—are associated with lower risks of coronary heart disease. Cholesterol-lowering therapy may, therefore, be worthwhile for individuals at high risk of coronary heart disease events irrespective of their presenting cholesterol levels. Observational studies also suggest that increased dietary intake of antioxidant vitamins may be associated with lower risks of coronary heart disease. The present randomized trial aims to assess reliably the effects on mortality and major morbidity of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of different categories of high-risk patients.
Methods and Results Men and women aged 40 to 80 years were eligible provided they were considered to be at elevated risk of coronary heart disease death because of past history of myocardial infarction or other coronary heart disease, occlusive disease of non-coronary arteries, diabetes mellitus or treated hypertension; had baseline blood total cholesterol of 3·5mmol.l–1or greater; and no clear indications for, or contraindications to, either of the study treatments. Eligible patients who completed a pre-randomization run-in phase on active treatment were randomly allocated to receive simvastatin (40mg daily) or matching placebo tablets and, in a ‘2x2 factorial’ design, antioxidant vitamins (600mg vitamin E, 250mg vitamin C and 20mg beta-carotene daily) or matching placebo capsules. Follow-up visits after randomization are scheduled at 4, 8 and 12 months, and then 6-monthly, for at least 5 years.Between July 1994 and May 1997, 15454 men and 5082 women were randomized, with 9515 aged over 65 years at entry. Diagnostic criteria overlapped, with 8510 (41%) having had myocardial infarction (most of whom were either female, or elderly or with low blood cholesterol), 4869 (24%) some other history of coronary heart disease, 3288 (16%) cerebrovascular disease, 6748 (33%) peripheral vascular disease, 5963 (29%) diabetes mellitus (of whom 3985 had no history of coronary heart disease) and 8455 (41%) treated hypertension. Baseline non-fasting total cholesterol levels were less than 5·5mmol.l–1in 7882 (38%) participants, and LDL (low density lipoprotein) cholesterol less than 3·0mmol.l–1in 6888 (34%).During a mean follow-up of 25 months (range: 13 to 47 months), no significant differences had been observed between the treatment groups in the numbers of patients with muscle symptoms, other possible side-effects leading to termination of study treatment, or elevated liver and muscle enzymes. After 30 months of follow-up, 81% of randomized patients remained compliant with taking their study simvastatin or placebo tablets, and allocation to simvastatin produced average reductions in non-fasting blood total and LDL cholesterol of about 1·5–1·6mmol.l–1and 1·1–1·2mmol.l–1respectively. Eighty-seven per cent of patients remained compliant with taking their vitamin or placebo capsules, and allocation to the vitamin supplement produced an average increase in plasma vitamin E levels of about 24µmol.l–1. Based on this initial follow-up period, the estimated annual rate of non-fatal myocardial infarction or fatal coronary heart disease is 2·4%, annual stroke rate is 1·3%, and annual all-cause mortality rate is 2·2%.
Conclusion The Heart Protection Study is large, it has included a wide range of patients at high risk of vascular events, and the treatment regimens being studied are well-tolerated and produce substantial effects on blood lipid and vitamin levels. The study should, therefore, provide reliable evidence about the effects of cholesterol-lowering therapy and of antioxidant vitamin supplements on all-cause or cause-specific mortality and major morbidity in a range of different categories of individuals for whom uncertainty remains about the balance of benefits and risks of these treatments.
Key Words: Randomized trial • cholesterol-lowering • simvastatin • antioxidant vitamins • coronary heart disease
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. T. Schumock and A. S. Pickard Comparative effectiveness research: Relevance and applications to pharmacy Am. J. Health Syst. Pharm., July 15, 2009; 66(14): 1278 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Reynolds, A. Mardani, P. J. Twomey, and A. S. Wierzbicki Targeted versus global approaches to the management of hypercholesterolaemia Perspectives in Public Health, September 1, 2008; 128(5): 248 - 254. [Abstract] [PDF]
|
|
|
|
 |
|
 T. R. Pedersen Overview of clinical trials on calcific aortic stenosis Eur. Heart J. Suppl., July 1, 2008; 10(suppl_E): E31 - E40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Paulsen, C. Holm, J. N. Bech, J. Starklint, and E. B. Pedersen Effects of statins on renal sodium and water handling: Acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1556 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Collins, G. Rosano, C. Casey, C. Daly, M. Gambacciani, P. Hadji, R. Kaaja, T. Mikkola, S. Palacios, R. Preston, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists Eur. Heart J., August 2, 2007; 28(16): 2028 - 2040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Silverman Ethical Issues during the Conduct of Clinical Trials Proceedings of the ATS, May 1, 2007; 4(2): 180 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Heart Protection Study Collaborative Group,* N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study J. Am. Coll. Cardiol., January 23, 2007; 49(3): 311 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hilbrich and P. Sleight Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials Eur. Heart J., September 2, 2006; 27(18): 2158 - 2164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Statins for primary prevention in type 2 diabetes DTB, August 1, 2006; 44(8): 57 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Keavney, J. Danesh, S. Parish, A. Palmer, S. Clark, L. Youngman, M. Delepine, M. Lathrop, R. Peto, R. Collins, et al. Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization' Int. J. Epidemiol., August 1, 2006; 35(4): 935 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Rief, J. Avorn, and A. J. Barsky Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects Arch Intern Med, January 23, 2006; 166(2): 155 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. P. T. James The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients Eur. Heart J. Suppl., November 1, 2005; 7(suppl_L): L44 - L48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N Hathcock, A. Azzi, J. Blumberg, T. Bray, A. Dickinson, B. Frei, I. Jialal, C. S Johnston, F. J Kelly, K. Kraemer, et al. Vitamins E and C are safe across a broad range of intakes Am. J. Clinical Nutrition, April 1, 2005; 81(4): 736 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schneider, B. Verges, A. Klein, E. R. Miller, V. Deckert, C. Desrumaux, D. Masson, P. Gambert, J.-M. Brun, J. Fruchart-Najib, et al. Alterations in Plasma Vitamin E Distribution in Type 2 Diabetic Patients With Elevated Plasma Phospholipid Transfer Protein Activity Diabetes, October 1, 2004; 53(10): 2633 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Keavney, A. Palmer, S. Parish, S. Clark, L. Youngman, J. Danesh, C. McKenzie, M. Delepine, M. Lathrop, R. Peto, et al. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk Int. J. Epidemiol., October 1, 2004; 33(5): 1002 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Coull Statin Therapy After Acute Ischemic Stroke in the Heart Protection Study: Is the Role in Recurrent Stroke Prevention Now Defined? Stroke, September 1, 2004; 35(9): 2233 - 2234. [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Thomas, P. Chook, M. Qiao, X. S. Huang, H. C. Leong, D. S. Celermajer, and K. S. Woo Deleterious Impact of "High Normal" Glucose Levels and Other Metabolic Syndrome Components on Arterial Endothelial Function and Intima-Media Thickness in Apparently Healthy Chinese Subjects: The CATHAY Study Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 739 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, F. Bachmann, C. Baigent, C. Bode, R. De Caterina, B. Charbonnier, D. Fitzgerald, J. Hirsh, S. Husted, J. Kvasnicka, et al. Expert Consensus Document on the Use of Antiplatelet Agents: The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology Eur. Heart J., January 2, 2004; 25(2): 166 - 181. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Werba, E. Tremoli, P. Massironi, M. Camera, A. Cannata, F. Alamanni, P. Biglioli, and A. Parolari Statins in coronary bypass surgery: rationale and clinical use Ann. Thorac. Surg., December 1, 2003; 76(6): 2132 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Aronow, G. M. Novaro, M. S. Lauer, D. M. Brennan, A. M. Lincoff, E. J. Topol, D. J. Kereiakes, and S. E. Nissen In-Hospital Initiation of Lipid-Lowering Therapy After Coronary Intervention as a Predictor of Long-term Utilization: A Propensity Analysis Arch Intern Med, November 24, 2003; 163(21): 2576 - 2582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. P. Yang, D. Yan, C. Qiao, R. J. Liu, J.-G. Chen, J. Li, M. Schneider, L. Lagrost, X. Xiao, and X.-C. Jiang Increased Atherosclerotic Lesions in ApoE Mice With Plasma Phospholipid Transfer Protein Overexpression Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1601 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. Marz, J. P. D. Reckless, and E. A. Stein Risk for Myopathy With Statin Therapy in High-Risk Patients Arch Intern Med, March 10, 2003; 163(5): 553 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. I.L. Berk-Planken, N. Hoogerbrugge, R. P. Stolk, A. H. Bootsma, and H. Jansen Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes: Effect of sex and the LIPC promoter variant Diabetes Care, February 1, 2003; 26(2): 427 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Hugenholtz Greek technology or mythology? Eur. Heart J., November 1, 2002; 23(21): 1639 - 1639. [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Jaff Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options Angiology, November 1, 2002; 53(6): 627 - 633. [Abstract] [PDF]
|
|
|
|
|
|
A. M.W. Spijkerman, M. C. Adriaanse, J. M. Dekker, G. Nijpels, C. D.A. Stehouwer, L. M. Bouter, and R. J. Heine Diabetic Patients Detected by Population-Based Stepwise Screening Already Have a Diabetic Cardiovascular Risk Profile Diabetes Care, October 1, 2002; 25(10): 1784 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Youngman, S. Clark, S. Manley, R. Peto, and R. Collins Reliable Measurement of Glycated Hemoglobin in Frozen Blood Samples: Implications for Epidemiologic Studies Clin. Chem., September 1, 2002; 48(9): 1627 - 1629. [Full Text] [PDF]
|
|
|
|
|
|
A.M. Gotto Guidelines and global risk: a U.S. perspective Eur. Heart J. Suppl., September 1, 2002; 4(suppl_F): F7 - F11. [Abstract] [PDF]
|
|
|
|
|
|
J.E. Deanfield The management of special patient populations Eur. Heart J. Suppl., September 1, 2002; 4(suppl_F): F19 - F23. [Abstract] [PDF]
|
|
|
|
 |
|
 X.-C. Jiang, A. R. Tall, S. Qin, M. Lin, M. Schneider, F. Lalanne, V. Deckert, C. Desrumaux, A. Athias, J. L. Witztum, et al. Phospholipid Transfer Protein Deficiency Protects Circulating Lipoproteins from Oxidation Due to the Enhanced Accumulation of Vitamin E J. Biol. Chem., August 23, 2002; 277(35): 31850 - 31856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Marso Optimizing the diabetic formulary: beyond aspirin and insulin J. Am. Coll. Cardiol., August 21, 2002; 40(4): 652 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Olshansky, L. Hayflick, and B. A. Carnes Position Statement on Human Aging J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2002; 57(8): B292 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Plotkin, S. Miller, S. Nakajima, E. Peskin, R. Burkman, D. Richardson, Y. Mitchel, J. Waldstreicher, M. Liu, D. Shapiro, et al. Lowering Low Density Lipoprotein Cholesterol with Simvastatin, a Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Does Not Affect Luteal Function in Premenopausal Women J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3155 - 3161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Olshansky, L. Hayflick, and B. A. Carnes Position Statement on Human Aging Sci. Aging Knowl. Environ., June 19, 2002; 2002(24): pe9 - 9. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Mcintyre, S. Kerr, B. Kennon, and M. Small The Glasgow Chart -- a simple method for calculation of cardiovascular risk in type 2 diabetes The British Journal of Diabetes & Vascular Disease, May 1, 2002; 2(3): 208 - 210. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Gotto Jr Statins: Powerful Drugs for Lowering Cholesterol: Advice for Patients Circulation, April 2, 2002; 105(13): 1514 - 1516. [Full Text] [PDF]
|
|
|
|
|
|
P. Libby and M. Aikawa Vitamin C, Collagen, and Cracks in the Plaque Circulation, March 26, 2002; 105(12): 1396 - 1398. [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ, January 12, 2002; 324(7329): 71 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Brown, X.-Q. Zhao, A. Chait, L. D. Fisher, M. C. Cheung, J. S. Morse, A. A. Dowdy, E. K. Marino, E. L. Bolson, P. Alaupovic, et al. Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease N. Engl. J. Med., November 29, 2001; 345(22): 1583 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Waters and P. Y. Hsue Low-Density-Lipoprotein Cholesterol Goals for Patients With Coronary Disease: Treating Between the Lines Circulation, November 27, 2001; 104(22): 2635 - 2637. [Full Text] [PDF]
|
|
|
|
|
|
J. C. LaRosa Prevention and Treatment of Coronary Heart Disease: Who Benefits? Circulation, October 2, 2001; 104(14): 1688 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Davidson Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 219 - 229. [Abstract] [PDF]
|
|
|
|
|
|
S. A. Grover, L. Coupal, and H. Zowall Response to Egede Diabetes Care, July 1, 2001; 24(7): 1306 - 1307. [Full Text] [PDF]
|
|
|
|
 |
|
 J. ARMITAGE and R. COLLINS Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials Heart, October 1, 2000; 84(4): 357 - 360. [Full Text]
|
|
|
|
|
|
The Heart Outcomes Prevention Evaluation Study Inv Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients N. Engl. J. Med., January 20, 2000; 342(3): 154 - 160. [Abstract] [Full Text] [PDF]
|
|